# Inovio Pharmaceuticals, Inc. (INO)

> Inovio Pharmaceuticals, Inc. (INO) trades at $1.76 (+2.92%) as of 7:59:56 PM EST on Nov 20, 2026, +109.80% over the past month. Market cap is $329.66M, with 1.8 days to cover in short interest.

Canonical: https://massive.com/quote/ino
Data as of: 2026-11-21T00:59:56.296Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$1.76** +0.05 (+2.92%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$1.84** +0.08 (+4.54%)
As of 7:59:56 PM EST on Nov 20, 2026 · After hours

## Stock performance

How Inovio Pharmaceuticals, Inc. (INO) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +2.92% |
| 1W | +23.08% |
| 1M | +109.80% |
| YTD | +1.15% |
| 1Y | -2.76% |
| 52-wk range | $0.56 – $2.72 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for INO: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $1.62 – $1.78 |
| Open | $1.73 |
| Prev close | $1.71 |
| Volume | 7.92M |
| Market cap | $329.66M |
| Shares out | 110.18M |

## Valuation and profitability ratios

Valuation and profitability ratios for Inovio Pharmaceuticals, Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 1102.91 |
| P/B | -9.72 |
| P/FCF | — |
| ROE | 209.7% |
| ROA | -118.3% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[Inovio Pharmaceuticals, Inc. (INO) insider trading](https://massive.com/quote/ino/insider-trading.md): open-market Form 4 buys and sells by Inovio Pharmaceuticals, Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events Inovio Pharmaceuticals, Inc. has disclosed to the SEC on Form 8-K.

- Nov 17, 2026 · Director appointment
  “Effective November 13, 2026, the Board of Directors (the "Board") of Inovio Pharmaceuticals, Inc. (the "Company") increased the size of the Board from eight to nine directors and appointed Jeffrey Libson to fill the newly created directorship. Mr. Libson will hold office until the Company's 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or his earlier death, resignation or removal.”
- Nov 10, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 10, 2026, Inovio Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter and nine months ended September 30, 2026.”
- Nov 9, 2026 · Underwriting agreement
  “On November 5, 2026, Inovio Pharmaceuticals, Inc. entered into an underwriting agreement with Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters, relating to the issuance and sale by the Company in a public offering.”
- Nov 2, 2026 · Product or service launch
  “VOCERYQ was approved in combination with CELLECTRA® 5PSP, the Company's proprietary DNA medicine delivery device. The Company expects to make VOCERYQ available to order and ship in approximately 60 days and anticipates full field deployment during the first quarter of 2027.”
- Oct 6, 2026 · Bylaw amendment
  “On October 6, 2026, the Board of Directors (the "Board") of Inovio Pharmaceuticals, Inc. (the "Company") approved and adopted an amendment (the "Bylaws Amendment") to the Amended and Restated Bylaws of the Company, effective immediately. The Bylaws Amendment adds a new Article 12 (Exclusive Forum), which provides that, unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for certain specified actions... In addition, the Bylaws Amendment provides that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.”

## Dividend history and stock splits

Inovio Pharmaceuticals, Inc.'s recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-12 · Jan 25, 2024
- 1-for-4 · Jun 6, 2014

## Similar companies

Public companies in a similar business to Inovio Pharmaceuticals, Inc..

- [MRNA](https://massive.com/quote/mrna.md) Moderna, Inc. Common Stock (-2.17%)

Daily change in the latest session, 15-minute delayed.

## INO short interest

How heavily INO is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 1.8 |
| Short interest | 22.1M |
| Avg volume | 12.15M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## INO news

The latest news and headlines about Inovio Pharmaceuticals, Inc. (INO).

- [PGEN Q3 Earnings Call Highlights Launch Momentum and Competition](https://www.zacks.com/stock/news/3026475/pgen-q3-earnings-call-highlights-launch-momentum-and-competition?cid=CS-ZC-FT-analyst_blog_plus|earnings_call_takeaways-3026475) · Zacks Investment Research · Nov 9, 2026 · positive sentiment
- [Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?](https://www.zacks.com/stock/news/3020717/precigen-gears-up-to-report-q3-earnings-what-can-investors-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-3020717) · Zacks Investment Research · Nov 2, 2026 · negative sentiment
- [FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer](https://www.zacks.com/stock/news/3003006/fda-backs-pfe-s-tukysa-combo-in-front-line-maintenance-breast-cancer?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-3003006) · Zacks Investment Research · Oct 8, 2026 · positive sentiment
- [PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?](https://www.zacks.com/stock/news/2998371/pgen-vs-irwd-which-biotech-stock-offers-better-growth-potential?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2998371) · Zacks Investment Research · Sep 30, 2026 · positive sentiment
- [Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 \| Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care](https://www.globenewswire.com/news-release/2026/09/30/3371632/28124/en/head-and-neck-squamous-cell-carcinoma-hnscc-market-insights-epidemiology-and-market-forecast-2036-set-to-reach-2-56-billion-as-hpv-targeted-vaccines-reshape-care.html) · GlobeNewswire Inc. · Sep 30, 2026 · positive sentiment

## About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 112 |
| Listed | Dec 8, 1998 |

[Company website](https://www.inovio.com)

## FAQ

### What is the Inovio Pharmaceuticals, Inc. (INO) stock price today?

Inovio Pharmaceuticals, Inc. (INO) is trading at $1.76 (+2.92% on the day) as of 7:59:56 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Inovio Pharmaceuticals, Inc.?

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases.

### What is the short interest in INO?

As of Oct 30, 2026, INO has 22.1M shares short and 1.8 days to cover.

### What exchange is INO listed on?

Inovio Pharmaceuticals, Inc. (INO) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time INO quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=INO`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Inovio Pharmaceuticals, Inc. (INO) insider trading](https://massive.com/quote/ino/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
